Experimental data showed that nintedanib attenuated Wnt3a-induced ColIa1, Fn, and α-SMA expression in vitro, suggesting that nintedanib treatment rebalanced the accumulation of Wnt3a-induced ECM components, which is crucial for the amelioration of pulmonary fibrosis. The gene discussed is ACTA1; the disease is pulmonary fibrosis.